Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No HPO annotations are available for this condition.
Age of onset: at birth.
Clinical Description – Classic WFS1 Spectrum Disorder Classic WFS1 spectrum disorder (WFS1-SD) is characterized by childhood-onset diabetes mellitus and progressive optic atrophy, with variable hearing impairment/ deafness, diabetes insipidus, neurologic abnormalities, and psychiatric abnormalities . Table 2. Select Features Associated with Classic WFS1 Spectrum Disorder
Classic WFS1-SD should be suspected in individuals with any of the following clinical findings and family history. Major clinical findings :
Diabetes mellitus (onset age usually 16 years)
Optic atrophy (onset age usually 16 years)
Additional clinical findings may include one or more of the following:
No approved treatments are currently available for early-onset nuclear cataract. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with classic or nonclassic WFS1 spectrum disorder (WFS1-SD), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. See also Wolfram Syndrome Clinical Management Guidelines, page 5, for recommended baseline investigations.
See also Wolfram Syndrome Clinical Management Guidelines, pages 6-12, for surveillance recommendations. Classic WFS1 Spectrum Disorder To monitor existing manifestations, the response of an individual with classic WFS1-SD to supportive care, and the emergence of new manifestations, the evaluations in are recommended. Table 7. Recommended Surveillance for Individuals with Classic WFS1 Spectrum Disorder
No clinical trials have been registered for early-onset nuclear cataract.
11 publications have been identified in PubMed for early-onset nuclear cataract. Research spans Basic Science / Preclinical (36%), Review / Meta-Analysis (27%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 4 | 36% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 6:51 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Feature | Common | Uncommon | Increases w/Age |
|---|---|---|---|
Diabetes mellitus, childhood onset | Diabetes mellitus, neonatal onset or adult onset | — | — |
Sensorineural hearing impairment | Cataracts | Cerebellar ataxia | Autonomic dysfunction |
Bowel dysfunction | Seizures | — | — |
Other endocrine findings | Central diabetes insipidus | — | — |
Hypogonadism | Hypothyroidism | Growth restriction | Based on data from , , , , , , , and 1. A comprehensive review of classic WFS1-SD, genotype-phenotype correlations, pathophysiology, and therapeutic strategies is available . |
Source: GeneReviews — "WFS1 Spectrum Disorder"
High-tone sensorineural hearing impairment
Cerebellar ataxia
Psychiatric illness
Neurogenic bladder (overactive or underactive)
Other endocrine findings:
Central diabetes insipidus
Delayed puberty, particularly in males, associated with hypogonadism
Non-autoimmune hypothyroidism
Structural congenital heart defects
Source: GeneReviews — "WFS1 Spectrum Disorder"
Wolfram syndrome type 2 (WS2) (OMIM 604928) is an autosomal recessive disorder caused by biallelic pathogenic variants in CISD2. Like classic WFS1 spectrum disorder (WFS1-SD), WS2 presents as a continuum of clinical features; however, the full clinical spectrum of WS2 abnormalities has not yet been fully established because so few affected individuals have been described. To date, the following clinical features have been reported in individuals with WS2: • Families of Palestinian Arab origin have been described with juvenile-onset diabetes mellitus, optic atrophy, high-frequency sensorineural hearing impairment, urinary tract dilatation, impaired kidney function, hypogonadism, and severe gastrointestinal ulcer and bleeding ; abnormal facial features were described in one family . • Diabetes insipidus, psychiatric abnormalities, and variable degrees of optic atrophy have been reported in individuals from Italy and Morocco . Peptic ulcers, mucocutaneous bleeding, and defective platelet aggregation were also described in a subset of these individuals. Note: A novel CISD2 pathogenic variant (c.215AG; p.Asn72Ser) was identified in an individual with clinical findings suggestive of classic WFS1-SD who did not have WFS1 pathogenic variants . Other Genetic Causes of Features Seen in WFS1 Spectrum Disorder Hearing impairment. See Genetic Hearing Loss Overview. Monogenic diabetes syndromes. See . Table 3. Monogenic Diabetes Syndromes in the Differential Diagnosis of WFS1 Spectrum Disorder
Gene(s)/ Genetic Mechanism | Differential Disorder | MOI | Selected Features of Differential Disorder |
|---|---|---|---|
Endocrine abnormalities | Eye findings | Hearing loss | Neurologic abnormalities ALMS1 |
Alstrm syndrome | AR | Insulin resistance/ type 2 DM often presents in 2nd decade. Other endocrine abnormalities incl hypogonadotropic hypogonadism in boys, polycystic ovaries in girls, hypothyroidism. Obesity common, leading to non-alcoholic fatty liver disease. | Cone-rod dystrophy presents as progressive visual impairment, photophobia, nystagmus starting between birth age 15 mos; no light perception by age 20 yrs in many persons. |
Bardet-Biedl syndrome | AR | Insulin resistance/ type 2 DM in adolescence or adulthood; male hypogonadotropic hypogonadism. Obesity is common. | Cone-rod dystrophy; night blindness usually evident by age 7-8 yrs; mean age of legal blindness is 15.5 yrs. |
DMPK | Myotonic dystrophy type 1 (DM1) | AD | DM is common in mild classic DM1. |
Source: GeneReviews — "WFS1 Spectrum Disorder"
Biomarker and diagnostic research for early-onset nuclear cataract has been reported in the published literature.
Recommended Evaluations Following Initial Diagnosis in Individuals with Classic or Nonclassic WFS1 Spectrum Disorder
System/Concern | Evaluation | Comment
| By diabetologist |
| Ophthalmologic eval | • Assess extraocular movement, best corrected visual acuity, visual evoked potentials.
Perform color vision testing, visual field testing, optical coherence tomography, fundus exam.
Optometry /or low-vision clinic | Assess for low-vision aids.
Sensorineural
hearing impairment | • Audiologic exam
Eval by speech-language therapist
| Incl:
Auditory brain stem responses to confirm pathology provide baseline
Evoked otoacoustic emissions to identify type of hearing impairment
Audiogram
Speech discrimination tests
Assessment for hearing aids; children w/profound infancy-onset deafness may require cochlear implant.
Neurologic
dysfunction | Neurologic exam incl brain MRI (if not performed previously) | Evaluate for:
Source: GeneReviews — "WFS1 Spectrum Disorder"
For a review of current and future therapeutic strategies, see . Classic WFS1-SD. An ongoing multicenter randomized double-blind controlled pivotal clinical trial is evaluating the use of sodium valproate to slow the progression of neurodegeneration (EudraCT Number 2017-001215-37). Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "WFS1 Spectrum Disorder"
View trials for early-onset nuclear cataract
System/Concern |
|---|
Evaluation |
|---|
Frequency |
|---|
Diabetes mellitus | Glycemic control | Every 3 mos |
Complications of diabetes mellitus | Nephropathy | Annual screening starting at age 12 yrs Retinopathy |
Sensorineural hearing impairment | Audiogram incl assessment of speech discrimination | Every 1-2 yrs Neurologic |
Activities of daily living mobility | Physical medicine, OT/PT assessment of mobility, self-help skills | Per treating clinicians |
Dysphagia | For those w/o this concern previously: obtain history of swallowing/choking episodes refer to speech-language therapist as needed. | Annually For those known to have this concern |
Dysarthria | For those w/o this concern previously: obtain history of speech difficulties refer to speech-language therapist as needed. | Annually For those known to have this concern |
Source: GeneReviews — "WFS1 Spectrum Disorder"
3 |
27% |
Patient case studies | 2 | 18% |
Testing and diagnosis research | 1 | 9% |
Disease patterns and progression | 1 | 9% |
de Guimarães TAC (2026). [PMID: 42071308](https://pubmed.ncbi.nlm.nih.gov/42071308/). *Ophthalmic Genet*. [Diagnostic / Biomarker]
Ni Y (2026). [PMID: 41876404](https://pubmed.ncbi.nlm.nih.gov/41876404/). *Aging cell*. [Basic Science / Preclinical]
Gong X (2026). [PMID: 42039128](https://pubmed.ncbi.nlm.nih.gov/42039128/). *Front Endocrinol (Lausanne)*. [Case Report / Case Series]
Morales-Reyes R (2025). [PMID: 40780438](https://pubmed.ncbi.nlm.nih.gov/40780438/). *Archivos de la Sociedad Espanola de Oftalmologia*. [Case Report / Case Series]
Wei L (2025). [PMID: 40274784](https://pubmed.ncbi.nlm.nih.gov/40274784/). *Nature communications*. [Basic Science / Preclinical]
Zheng Y (2025). [PMID: 39423307](https://pubmed.ncbi.nlm.nih.gov/39423307/). *Brain : a journal of neurology*. [Epidemiology / Natural History]
Machna B (2025). [PMID: 41335529](https://pubmed.ncbi.nlm.nih.gov/41335529/). *Journal of physiology and pharmacology : an official journal of the Polish Physiological Society*. [Review / Meta-Analysis]
Jurca AD (2024). [PMID: 39064493](https://pubmed.ncbi.nlm.nih.gov/39064493/). *Medicina (Kaunas, Lithuania)*. [Review / Meta-Analysis]
Nagaoka T (2024). [PMID: 38874665](https://pubmed.ncbi.nlm.nih.gov/38874665/). *Japanese journal of ophthalmology*. [Basic Science / Preclinical]
Snead MP (2024). [PMID: 39349161](https://pubmed.ncbi.nlm.nih.gov/39349161/). *Progress in retinal and eye research*. [Basic Science / Preclinical]